Physician profile
Eric C Buxton
NPI 1134210362
$11,214.98
in general payments reported to CMS, 2019-2025
35 companies · $2,097 in 2025
The $2,097 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,008 · 2020: $1,423 · 2021: $1,564 · 2022: $1,767 · 2023: $1,603 · 2024: $1,753 · 2025: $2,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,414 · Education: $38.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,414.25 |
| Education | $38.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,791.72 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,580.53 | 2019-2025 | Evenity, Prolia, Tepezza |
| Antares Pharma, INC. | $1,176.45 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Novo Nordisk INC | $1,038.87 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $999.67 | 2019-2024 | Farxiga |
| Radius Health, INC. | $767.29 | 2019-2025 | Tymlos |
| Abbvie INC. | $693.02 | 2019-2025 | Synthroid |
| Tandem Diabetes Care, INC. | $375.79 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Halozyme INC | $287.43 | 2023 | |
| Ibsa Pharma INC. | $252.69 | 2019-2025 | Tirosint, Flector, Tirosint |
| Sanofi-Aventis U.S. LLC | $247.32 | 2019-2025 | |
| Insulet Corporation | $234.66 | 2019-2023 | Omnipod |
| Alexion Pharmaceuticals, INC. | $228.91 | 2022-2025 | Strensiq |
| Mannkind Corporation | $213.68 | 2021-2023 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.92 | 2020-2025 | Jardiance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $170.98 | 2022-2025 | Freestyle Libre 3 |
| Madrigal Pharmaceuticals | $162.26 | 2025 | Rezdiffra |
| Medtronic, INC. | $120.43 | 2021-2025 | Minimed 780g, Minimed 770g |
| Ascendis Pharma Endocrinology INC | $116.92 | 2023-2025 | Yorvipath |
| Horizon Therapeutics Plc | $95.72 | 2021-2022 | |
| Dexcom, INC. | $77.73 | 2024-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $60.82 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $49.62 | 2025 | |
| Lifescan, INC. | $49.43 | 2020-2021 | |
| Sequel Med Tech, LLC | $43.12 | 2025 | Twiist |
| Beta Bionics, INC. | $23.81 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Almatica Pharma LLC | $23.50 | 2025 | Teriparatide |
| Kyowa Kirin, INC. | $23.19 | 2025 | |
| Soleno Therapeutics, INC. | $21.79 | 2025 | Vykat Xr |
| Acella Pharmaceuticals, LLC | $20.68 | 2024 | NP Thyroid 60 |
| Verity Pharmaceuticals INC. | $20.00 | 2024 | Tlando |
| Amphastar Pharmaceuticals, INC. | $17.83 | 2025 | |
| Zealand Pharma US, INC. | $17.01 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.74 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Buxton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.